Investing

GSK says FDA extends review period for experimental drug momelotinib

Published

1 year ago

on

© Reuters. FILE PHOTO: GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) – British drugmaker GSK Plc on Friday said the U.S. Food and Drug Administration has extended the review period for its experimental drug momelotinib, which is designed to treat anaemic patients with a type of bone marrow cancer called myelofibrosis.

Momelotinib is not currently approved in any market.

Read the full article here

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version